Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Abstract Background In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. Methods Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥...

Full description

Bibliographic Details
Main Authors: William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Breast Cancer Research
Subjects:
Circulating tumor cells
Metastatic breast cancer
HER2
Trastuzumab-emtansine
Liquid biopsy
Online Access:http://link.springer.com/article/10.1186/s13058-019-1215-z

Internet

http://link.springer.com/article/10.1186/s13058-019-1215-z

Similar Items